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Abstract
Docetaxel chemotherapy is increasingly used in the treatment of castration-resistant prostate cancer.
Cutaneous toxicity is common with docetaxel, occurring in up to 75% of cases. We present an
unusual case of castration-resistant prostate cancer in which our patient developed recurrent but
transient episodes of skin rash following each cycle of docetaxel. Initially, the rash was attributed to
docetaxel cutaneous toxicity however a microbiological diagnosis of Trichophyton rubrum was
subsequently made. We postulated that dexamethasone pre-medication transiently suppressed anti-
fungal immunity, and indeed further flares were prevented by significantly reducing the dose of
dexamethasone while continuing treatment with docetaxel.
Introduction
Docetaxel chemotherapy is commonly used in castration-
resistant prostate cancer (CRPC). Cutaneous toxicity with
docetaxel is well recognised, manifesting in numerous
ways including palmar/plantar erythrodysaesthesia (PPE)
and nail changes (onycholysis, paronychia). We present a
fascinating case in which our patient developed recurrent
but transient episodes of skin rash resembling PPE
following each cycle of docetaxel. Initially docetaxel
cutaneous toxicity was suspected, however subsequently
a microbiological diagnosis of Trichophyton rubrum was
made. We postulated that dexamethasone pre-medication
transiently suppressed anti-fungal immunity, and indeed
further flares were prevented by significantly reducing the
dose of dexamethasone while continuing treatment with
docetaxel.
Case presentation
A 57 year old Caucasian male with CRPC commenced
docetaxel chemotherapy (75 mg/m
2 intravenous three-
weekly) and oral prednisolone (5 mg twice daily). Routine
dexamethasone pre-medication (8 mg twice daily for three
days starting one day pre-docetaxel) was given to prevent
docetaxel hypersensitivity reactions. From cycles two to
four he complained of an itchy, erythematous rash of his
feet. The rash commenced one to two days after receiving
docetaxel, lasted for seven to ten days, and then resolved
spontaneously. He had no prior dermatological history.
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Macedonian origin. He lived with his wife and was retired.
There was no relevant family history.
On examination, there was a sharply demarcated, erythe-
matous, macular rash involving the soles of his feet. There
was also non-tender onycholysis affecting both great toes.
Nail and skin scrapings were taken with Trichophyton
rubrum isolated on fungal culture. The patient continued
ondocetaxelat75mg/m
2forthenextthreecycles,however
a single dose of dexamethasone (8 mg intravenous) was
given as pre-medication one hour prior to docetaxel. The
patient also commenced oral terbinafine 250 mg daily for
four weeks. There were no further flares of T. Rubrum and
no hypersensitivity reactions. Treatment was stopped after
seven cycles of docetaxel because of progressive disease.
Discussion
The time course, distribution and appearance of therash in
our patient were not helpful in conclusively differentiating
docetaxel cutaneous toxicity from a fungal infection.
Initially, we had suspected PPE since docetaxel is a
common cause of PPE [1]. Moreover, there was a temporal
relationship between the rash and treatment with doc-
etaxel. On the other hand, this temporal relationship also
existed for dexamethasone. Additionally, the absence of
palmar involvement was somewhat unusual for PPE. After
making a diagnosis of T. Rubrum, we then faced the
dilemma of how best to prevent further flares while not
compromising anti-cancer treatment.
We postulated that thedexamethasone pre-medication was
causing transient suppression of anti-fungal immunity
thereby predisposing to recurrent flares of T. Rubrum. Cell-
mediated immunity (CMI) plays a critical role in defence
against fungal infections [2]. Glucocorticoid therapy is a
major risk factor for fungal infections and can impair CMI
in numerous ways. This includes reduction of neutrophil
and macrophage accumulation at inflammatory sites [3,4],
and impaired phagocytic and microbicidal function of
macrophages [5]. In addition glucocorticoids induce
profound lymphopaenia, predominantly of T-cells and
particularly CD4 cells. Importantly, glucocorticoids also
reduce Th1 CD4 cell numbers more than Th2 CD4 cells
[6]. This preferential differentiation is significant since
Th1-mediated CMI is required for clearance of fungal
infections [7].
Like dexamethasone, prednisolone is a glucocorticoid but
it was unlikely to have contributed since it is less potent
than dexamethasone. Additionally, the dose of predniso-
lone was low and there was no temporal relationship to
the rash. We did consider the role of docetaxel, which can
theoretically impair CMI since it causes neutropaenia as
well as CD4 and CD8 lymphopaenia [8]. However, we felt
that dexamethasone was more likely to have contributed
to the flares of T. Rubrum and accordingly we substantially
reduced the dose of dexamethasone pre-medication while
maintaining the dose of docetaxel. This resulted in no
further flares during three cycles of treatment, suggesting
that we were correct. Our patient was also treated with oral
anti-fungal therapy, which was undoubtedly important in
preventing further flares.
Conclusions
With increasing use of docetaxel for CRPC, clinicians are
likely to encounter patients with skin-related problems.
Giventhatdocetaxelcausesskintoxicityinasmanyas75%
of patients [1], docetaxel is likely to be the culprit in the
vast majority of cases. Our case, while being a somewhat
unusual presentation of cutaneous fungal infection, high-
lights the importance of considering other causes.
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